Table 1 Characteristics of the 95 enrolled patients
Age | 67 (57–77) |
Male/female | 58/37 |
Body weight (kg) | 59.7 (48.7–66.6) |
APACHE II score | 17 (14–22) |
Chronic heart failure | 13 |
Furosemide use before ICU | 25 |
Doses of furosemide before ICU (mg) | 30 (20–55) |
Indication for ICU admission | Â |
 Cardiovascular | 11 |
 Cerebrovascular | 12 |
 Pulmonary | 17 |
 Sepsis | 17 |
 Others | 38 |
Baseline serum creatinine (mg/dl) | 0.8 (0.51–0.98) |
Serum creatinine at hospitalization (mg/dl) | 0.89 (0.64–1.30) |
Serum creatinine at ICU admission (mg/dl) | 0.97 (0.60–1.37) |
Serum creatinine at furosemide administration (mg/dl) | 1.09 (0.68–1.40) |
Serum albumin at furosemide administration (g/dL) | 2.9 (2.5–3.2) |
AKI stage at ICU admission | Â |
 No AKI | 55 |
 Stage 1 | 29 |
 Stage 2 | 11 |
AKI stage at furosemide administration | Â |
 No AKI | 44 |
 Stage 1 | 34 |
 Stage 2 | 17 |
AKI stage at 1Â week | Â |
 No AKI | 34 |
 Stage 1 | 23 |
 Stage 2 | 20 |
 Stage 3 | 18 |
Length of hospitalization (days) | 50 (25–93) |
Length of ICU stay (days) | 6 (3–11) |
Plasma NGAL at furosemide administration (ng/mL) | 147 (78–309) |
Urinary L-FABP at furosemide administration (μg/gCr) | 39.9 (15.1–208) |
Urinary NAG at furosemide administration (U/gCr) | 3.5 (2.0–6.4) |
Dose of furosemide (mg) | 10 (10–20) |